Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Infectious Diseases in Clinical Practice ; 30(5) (no pagination), 2022.
Article in English | EMBASE | ID: covidwho-2315547

ABSTRACT

This study aimed to demonstrate the association between high-dose corticosteroid administration and adverse outcomes in coronavirus disease 2019 patients. Data were collected retrospectively from medical records. The primary outcome was invasive mechanical ventilation or death, whichever occurred first. The secondary outcome was all-cause in-hospital mortality. The standard dose was defined as a daily dose of <=1.5 mg/kg of prednisolone or equivalent, and the high-dose was defined as >=250 mg of prednisolone or equivalent. Data were analyzed using frequentist and Bayesian logistic models. In addition, a propensity score-matched subgroup was analyzed for the association between high-dose corticosteroid use and adverse outcomes. A total of 1072 patients hospitalized between September 29, 2020, and April 20, 2021, were enrolled in the study. Of these, 188 patients (18%) had a primary outcome;55 patients (29%) died, and 133 (71%) required invasive mechanical ventilation. Higher age was associated with adverse outcomes in all analyses. Standard dose corticosteroid use was found to be protective (odds ratio [95% confidence interval], 0.53 [0.35-0.81]) in the final logistic model. Point estimates in the propensity score-matched subgroup did not encourage high-dose corticosteroid use (odds ratio [95% confidence interval], 3.06 [0.98-9.50]). The posterior probability density distributions generated by the Bayesian logistic model implicated standard-dose corticosteroid use as protective (80% credible intervals, -0.839 to -0.313), whereas it implicated high-dose corticosteroid use as associated with adverse outcomes (80% credible intervals, 0.163-0.941). This study found high-dose corticosteroid (>=250 mg prednisolone daily) use associated with adverse outcomes. Copyright © Wolters Kluwer Health, Inc. All rights reserved.

2.
Eurasian Journal of Pulmonology ; 24(1):47-53, 2022.
Article in English | Web of Science | ID: covidwho-2155516

ABSTRACT

BACKGROUND AND AIM: We aimed to examine the demographic, clinical, and imaging characteristics of patients with COVID???19 pneumonia and also to identify the factors affecting mortality. MATERIALS AND METHODS: This study was designed as a retrospective single???center observational study. A total of 126patients with COVID???19 pneumonia who were polymerase chain reaction confirmed and underwent thorax computer tomography(CT) were analyzed. The patients' demographic and clinical data were obtained from the electronic medical record. Thorax CT findings were re???evaluated retrospectively by thoracic radiologists according to the severe acute respiratory syndrome coronavirus 2 pneumonia guidelines of the Radiological Society of North America. The extent of lesions was evaluated by CT lobe score, which was the sum of individual lobe scores(0-5 point) of the lungs. RESULTS: The mean age of the patients was 60.4 +/- 18.6years and 54%(n=68) were male. The most common symptoms included cough, fever, and shortness of breath. The average time interval between the onset of symptoms and thorax CT acquisition was 6.6 +/- 8.3days. The most common radiological findings included ground???glass opacity(98.4%), consolidation(72.2%), and vascular enlargement(69.8%), respectively. The deceased patients had more common consolidation, vascular enlargement, and high lobe scores in thorax CT as compared to survivors. According to logistic regression analysis age(P=0.003), lobe score(P=0.001), numbers of comorbidities(P=0.017), symptoms duration(P=0.034), and vascular enlargement(P=0.045) were independent risk factors on 30???day mortality. CONCLUSION: This study indicated that age, symptoms duration, the number of comorbidities, lobe score, and vascular enlargement in thorax CT are associated with the prognosis of COVID???19 pneumonia

3.
Niger J Clin Pract ; 25(10): 1660-1665, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2100049

ABSTRACT

Aim and Background: Because of there is no sufficient evidence showing a relationship between blood types and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, this study was planned to investigate the effects of ABO blood group on the clinical outcomes of SARS-CoV-2 infection. Patients and Methods: The data of the patients were examined retrospectively. The patients who were hospitalized in wards or intensive care unit, constituted the study group. The patients who presented to the hospital because of other causes and whose blood type examinations were performed, were included in the control group. Results: The study group consisted of 406 six patients were diagnosed with SARS-CoV-2 infection. Control group consisted of 38079 patients whose blood group was determined for any reason in the same period. The rate of Rh negativity was significantly higher in the patient group (p = 0,01). Hospitalization duration in intensive care was significantly longer in the blood type A and AB groups compared to the blood type O group (p = 0,03). Conclusion: Our results are in agreement with other studies suggesting that blood group O individuals are somewhat more resistant to clinically overt infection with SARS-CoV-2 than other blood groups. In addition, Rh negativity may also be an individual risk factor for SARS-CoV-2 infection.


Subject(s)
COVID-19 , Humans , SARS-CoV-2 , Retrospective Studies , Blood Grouping and Crossmatching , ABO Blood-Group System
4.
Anatolian Journal of Cardiology ; 24(SUPPL 1):62-63, 2020.
Article in English | EMBASE | ID: covidwho-1175928

ABSTRACT

Background and Aim: A new infectious outbreak sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now spreading all around the world. The aim of this study was to evaluate the prognostic value of left ventricular global longitudinal strain (LV-GLS) and right ventricular longitudinal strain (RV-LS) in patients with coronavirus disease 2019 (COVID-19). Methods: In this prospective, single-center study, data were gathered from patients treated for COVID-19 between April 15 and April 30, 2020. Two-dimensional echocardiography (2-DE) and speckle tracking echocardiography (STE) images were obtained for all patients. Patients were divided into three groups: those with severe COVID-19 infection, those with non-severe COVID-19 infection, and those without COVID-19 infection (the control group). Data regarding clinical characteristics and laboratory findings were obtained from electronic medical records. The primary endpoint was in-hospital mortality. Results: A total of 100 patients hospitalized for COVID-19 were included in this study. The mean age of the severe group (n=44) was 59.1±12.9, 40% of whom were male. The mean age of the non-severe group (n=56) was 53.7±15.1, 58% of whom were male. Of these patients, 22 died in the hospital. In patients in the severe group, LV-GLS and RV-LS were decreased compared to patients in the non-severe and control groups (LVGLS: -14.5±1.8 vs. -16.7±1.3 vs. -19.4±1.6, respectively [p<0.001];RV-LS: -17.2±2.3 vs. -20.5±3.2 vs. -27.3±3.1, respectively [p<0.001]). The presence of cardiac injury, D-dimer, arterial oxygen saturation (SaO2), LV-GLS (OR:1.63, 95% confidence interval [CI] 1.08-2.47;p=0.010) and RV-LS (OR:1.55, 95% CI 1.07-2.25;p=0.019) were identified as independent predictors of mortality via multivariate analysis. Conclusions: LV-GLS and RV-LS are independent predictors of in-hospital mortality in patients with COVID-19.

SELECTION OF CITATIONS
SEARCH DETAIL